Information Technology Reference
In-Depth Information
Tsume, Y. and Amidon, G.L. (2010) 'The biowaiver extension for BCS class III
drugs: the effect of dissolution rate on the bioequivalence of BCS class III
immediate-release drugs predicted by computer simulation', Mol. Pharm. ,
7(4): 1235-43.
Tubic, M., Wagner, D., Spahn-Langguth, H., Bolger, M.B., and Langguth, P.
(2006) ' In silico modeling of non-linear drug absorption for the P-gp substrate
talinolol and of consequences for the resulting pharmacodynamic effect',
Pharm. Res. , 23(8): 1712-20.
Tubic-Grozdanis, M., Bolger, M.B., and Langguth, P. (2008) 'Application of
gastrointestinal simulation for extensions for biowaivers of highly permeable
compounds', AAPS J. , 10(1): 213-26.
US Food and Drug Administration Center for Drug Evaluation and Research.
(1997) Guidance for Industry : Extended release oral dosage forms: development,
evaluation, and application of in vitro / in vivo correlations, Rockville (MD): US
Food and Drug Administration; Available at: http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.
pdf (accessed 3 June 2012).
US Food and Drug Administration Center for Drug Evaluation and Research.
(2000) Guidance for Industry : Waiver of in vivo bioavailability and
bioequivalence studies for immediate-release solid oral dosage forms based on
a Biopharmaceutics Classifi cation System, Rockville (MD): US Food and Drug
Administration; Available at: http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf
(accessed on 3 June 2012).
Wei, H. and
Löbenberg, R. (2006) 'Biorelevant dissolution media as a predictive
tool for glyburide a class II drug', Eur. J. Pharm. Sci. , 29(1): 45-52.
Wei, H., Dalton, C., Di Maso, M., Kanfer, I., and Löbenberg, R. (2008)
'Physicochemical characterization of fi ve glyburide powders: a BCS based
approach to predict oral absorption', Eur. J. Pharm. Biopharm. , 69(3): 1046-56.
Welling, P.G. (1996) 'Effects of food on drug absorption', Annu. Rev. Nutr. , 16:
383-415.
WHO Expert Committee on Specifi cations for Pharmaceutical Preparations
(2006) Fortieth report . WHO technical report series No. 937. Geneva:
World Health Organization. Available at: http://whqlibdoc.who.int/trs/who_
trs_937_eng.pdf (accessed 3 Jun 2012).
Willmann, S., Lippert, J., Sevestre, M., Solodenko, J., Fois, F. , and Schmitt, W.
(2003) 'PK-Sim ® : a physiologically based pharmacokinetic 'whole-body'
model', BioSilico , 1(4): 121-4.
Willmann, S., Schmitt, W. , Keldenich, J., Lippert, J., and Dressman, J.B. (2004)
'A physiological model for the estimation of the fraction dose absorbed in
humans', J. Med. Chem. , 47(16): 4022-31.
Wu, C.Y. and Benet, L.Z. (2005) 'Predicting drug disposition via application of
BCS: transport/absorption/elimination interplay and development of a
Biopharmaceutics Drug Disposition Classifi cation System', Pharm. Res. ,
22(1): 11-23.
Wu, Y. , Loper, A., Landis, E., Hettrick, L., Novak, L., et al. (2004) 'The role of
biopharmaceutics in the development of a clinical nanoparticle formulation of
MK-0869: a beagle dog model predicts improved bioavailability and
￿
￿
￿
 
Search WWH ::




Custom Search